Cargando…
Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()
BACKGROUND: Ectopic pregnancies are a leading cause of maternal mortality. Most are treated surgically. We evaluated the efficacy and safety of combining oral gefitinib (epidermal growth factor receptor inhibitor) with methotrexate to treat larger ectopic pregnancies. METHODS: We performed a phase I...
Autores principales: | Skubisz, Monika M., Tong, Stephen, Doust, Ann, Mollison, Jill, Johns, Terrance G., Neil, Peter, Robinson, Miranda, Bhattacharya, Siladitya, Wallace, Euan, Krzys, Nicole, Colin Duncan, W., Horne, Andrew W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085507/ https://www.ncbi.nlm.nih.gov/pubmed/29941341 http://dx.doi.org/10.1016/j.ebiom.2018.06.017 |
Ejemplares similares
-
Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol
por: Horne, Andrew W, et al.
Publicado: (2013) -
Conservative Management of Interstitial Pregnancy With Beta-hCG of Over 39,000 mIU/mL: A Case Report
por: Mayuga, Tom J, et al.
Publicado: (2022) -
Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study
por: Skubisz, Monika, et al.
Publicado: (2013) -
Efficacy of methotrexate therapy in patients with tubal pregnancy and a serum human chorionic gonadotropin level above 10,000 IU/L
por: Kim, Kidong, et al.
Publicado: (2014) -
1,000 ancient genomes uncover 10,000 years of natural selection in Europe
por: Le, Megan K., et al.
Publicado: (2022)